Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Dr. Reddy's Laboratories Ltd Common Stock
(NY:
RDY
)
14.28
-0.05 (-0.35%)
Official Closing Price
Updated: 6:30 PM EDT, May 22, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Dr. Reddy's Laboratories Ltd Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Give peace a chance
February 15, 2022
Israeli fabless semiconductor maker Tower was bought by Intel for $5.4 bn today.
Via
Talk Markets
Dr. Reddy's Laboratories Announces the Launch of Its Authorized Generic Version of VASOSTRICT® (vasopressin injection, USP) Vials in the U.S. Market
February 09, 2022
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
NYSE-Listed Pharma Co. Dr. Reddy's To Acquire German Medical Cannabis Firm Nimbus Health GmbH
February 04, 2022
Pharmaceutical company Dr. Reddy's Laboratories Ltd. (NYSE:RDY) has entered into a definitive agreement to acquire Nimbus Health GmbH, a medical cannabis-focused licensed pharmaceutical wholesaler from...
Via
Benzinga
Weakened Tech Stocks
February 03, 2022
There was a 0.5% rise in UK interest rates, twice what had been anticipated and moreover early, because of inflation risks.
Via
Talk Markets
Dr. Reddy's Laboratories Enters Into Definitive Agreement to Acquire German Medical Cannabis Firm Nimbus Health GmbH
February 03, 2022
From
Dr. Reddy's Laboratories Ltd.
Via
Business Wire
Dr. Reddy’s Included in S&P Global’s Sustainability Yearbook for the 2nd Year and Bloomberg Gender-Equality Index for the 5th Year in a Row
February 02, 2022
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
The Last Day In January
January 31, 2022
The market is suspicious of the moves up to right matters.
Via
Talk Markets
Earnings Scheduled For January 28, 2022
January 28, 2022
Companies Reporting Before The Bell • Oxford Lane Capital (NASDAQ:OXLC) is estimated to report earnings for its third quarter. • LyondellBasell Industries (NYSE:...
Via
Benzinga
Reddy's To Launch Generic Version Of Merck's COVID-19 Drug At $0.50/Pill: Reuters
January 04, 2022
India-based Dr Reddy's Laboratories Ltd (NYSE: RDY) will launch its generic version of Merck Co & Inc's (NYSE: MRK) COVID-19 antiviral pill, ...
Via
Benzinga
Happy New Year - Sunday Edition
January 02, 2022
Starting a new year - we look at tech, pharma and mining stocks and their goings-on.
Via
Talk Markets
Market Trend: Erratic And Unreliable
December 29, 2021
Given the risks of covid variants and hefty price rises, the stock market should not be as buoyant as it is.
Via
Talk Markets
A Bit Of Good News
December 22, 2021
US growth figures for Q3 were up from forecasts of 2.1% at 2.3% but well down from the prior quarter level of 6.7%.
Via
Talk Markets
Dr. Reddy's Laboratories Announces the Launch of Venlafaxine ER Tablets in the U.S. Market
December 09, 2021
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Dr. Reddy's Laboratories Announces the Launch of Valsartan Tablets, USP in the U.S. Market
December 09, 2021
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Prestige BioPharma and Dr. Reddy’s announce partnership to commercialize trastuzumab biosimilar in select countries in Latin America and Southeast Asia
December 08, 2021
From
Prestige BioPharma Ltd.
Via
Business Wire
5 Reasons Why Sensex Crashed, Tarsons Products' Lukewarm Debut, And Buzzing Stocks Today
November 29, 2021
Indian share markets, which ended deep in the red on Friday, are headed for a gap-up opening today following the trend on SGX Nifty.
Via
Talk Markets
Tuesday Market Overview
November 16, 2021
While gold gained modestly again today, cryptocurrencies fell hard.
Via
Talk Markets
Dr. Reddy's Ready To Make COVID-19 Antiviral From Pfizer - Reuters
November 16, 2021
Dr. Reddy's Laboratories Ltd (NYSE: RDY) said it was open to making Pfizer Inc's (NYSE: PFE) COVID-19 antiviral pill, Reuters reported. The new drugs can...
Via
Benzinga
Exposures
COVID-19
Dr. Reddy's Laboratories Announces the Launch of Ephedrine Sulfate Injection USP, 50 mg/mL, Single-Dose Vial in the U.S. Market
October 29, 2021
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Wednesday Market Coverage
October 20, 2021
Today gold rose again despite the active market for bitcoin and the lower Chinese demand for mine products like iron and coal.
Via
Talk Markets
Bitcoin Futures Arrive
October 19, 2021
Today you can finally hold Bitcoins via an exchange-traded fund.
Via
Talk Markets
The Daily Biotech Pulse: Entasis, Dermata Spike Higher On Positive Readouts, J&J Q3 EPS Beats Estimates, Wave Life Sciences Regains Right To CNS Portfolio
October 19, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Entasis Announces Positive Data For Late-Stage Study Of SUL-DUR In...
Via
Benzinga
Dr. Reddy's Laboratories Announces Approval for Lenalidomide Capsules from the U.S. Food and Drug Administration (USFDA)
October 19, 2021
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Dr. Reddy's Laboratories Announces the Launch of Carmustine for Injection, USP in the U.S. Market
October 15, 2021
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Indian Study Shows Merck's COVID-19 Antiviral Candidate Less Effective Against Moderate Infection: Reuters
October 08, 2021
According to a source with the Drug Controller General of India, Merck & Co Inc's (NYSE: MRK) antiviral drug molnupiravir has not shown "significant...
Via
Benzinga
Exposures
COVID-19
A Bit Of A Recovery
September 29, 2021
While Germany remains without a government, Japan has a new prime minister who will lead his party in the election this week.
Via
Talk Markets
Why This Citius Analyst Thinks The Biopharma's Shares Present 375% Upside Potential
September 10, 2021
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR)
Via
Benzinga
Dr Reddy's To Sell Its Anti-Cancer Agent To Citius Pharma
September 07, 2021
Citius Pharmaceuticals Inc has agreed to acquire anti-cancer agent E7777 from Dr. Reddy's Laboratories Ltd (NYSE: RDY). E7777 is an engineered IL-2-...
Via
Benzinga
Dr. Reddy’s Laboratories enters into definitive agreement with Citius Pharmaceuticals, Inc. to sell its rights to anti-cancer agent E7777 (denileukin diftitox)
September 04, 2021
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Mu - The Newest Worry
September 03, 2021
Today London and New York fell on the huge drop in new employment levels in August.
Via
Talk Markets
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.